Clinical Trial Update: JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure [Phase 1, Phase 2]

View source ↗

Summary

A NHLBI-sponsored Phase 1/2 trial is evaluating ruxolitinib, a JAK1/2 inhibitor, for relapsed/refractory immune bone marrow failure. The study includes severe a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aplastic Anemia
• Hypoplastic Myelodysplastic Syndrome
• T-cell Large Granular Lymphocytic Leukemia

Drugs mentioned

• Ruxolitinib (Jakafi) (ruxolitinib)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Severe Aplastic Anemia, Single Lineage Cytopenias, T-LGL | Phase 1, Phase 2 | Status: RECRUITING